Lung cancer is one of the most common malignancies in the world, representing about 1.6 million cases annually and over 10% of all new cancers. The most well-known risk factor for lung cancer is cigarette smoking which has become endemic in Asia.

The Asia-Pacific region has about one in six of all prostate cancer cases, and prostate cancer is the most diagnosed male cancer in China, Australia, and New Zealand. Globally, it is the second leading cause of cancer death.

The incidence of urological cancer has increased consistently in the recent years globally. Bladder cancer has become the ninth most common cancer worldwide, with over 400,000 new cases diagnosed each year. A majority of all bladder cancer cases occur in men in the less developed regions of the world due to environmental factors and smoking habits.

Non-alcoholic fatty liver diseases (NAFLD) are one of the most common liver disorder in developed countries and are particularly prevalent in Asian countries, especially in South Korea and Taiwan. Over a third of all industry-sponsored clinical studies initiated during the period (2015-2017) involved sites located in a country in which Novotech operates.

Hepatocellular carcinoma (HCC) and bile duct malignancies are highly prevalent in Asia, especially in South Korea and in Japan where the prevalence rate is about 5 times higher than in Western countries.

It is estimated that at least 2 billion people or one third of the world’s population have been infected with HBV. Approximately 240 million people or 6% of the world’s population are chronically infected and the Asia Pacific region represents three quarters of chronic HBV patients worldwide.

Gastric Cancer malignancies are highly prevalent in Asia, especially in South Korea and in Japan where the prevalence rate is about 10 times higher than in Western countries.